Improved MPO-AAV related experimental vasculitis animal model construction method
Through the combined induction method of PMA and PTU, an animal model of MPO-AAV-related vasculitis that is closer to the characteristics of human diseases was constructed, which solved the problem of insufficient pathological changes in the existing models and improved experimental efficiency and model Stability provides a more suitable platform for the research of MPO-AAV.
Patent Information
- Application Number
- CN202411163553.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-08
AI Technical Summary
The existing method for building an animal model of MPO-AAV-related vasculitis has insufficient pathological changes, long experimental cycles and high cost, and the renal pathological changes are not close enough to human disease manifestations, especially the insufficient formation of crescent glomerulonephritis .
By injecting PMA and PTU into Wistar Kyoto rats with intraperitoneal injection of PMA and oral PTU, it induces its pathological changes such as pulmonary vasculitis and crescent nephritis, improving the stability and efficiency of the model and reducing the experimental cost. .
A model construction that is closer to the characteristics of human diseases is achieved, which improves experimental efficiency and cost-effectiveness, and provides a more suitable platform for studying the pathogenesis of MPO-AAV and drug-targeted treatment.
Smart Images

Figure CN118901662A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of animal models of human diseases, and specifically relates to a method for constructing an improved MPO-AAV-related experimental vasculitis animal model. Background Art
[0002] Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a rare heterogeneous disease characterized by inflammation and necrosis of small and medium-sized blood vessels, accompanied by the presence of circulating serum ANCA. This systemic vasculitis is mainly divided into three clinical subtypes: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). The disease can affect multiple systems throughout the body, with lung and kidney damage being the most common. Its lesions are complex and diverse, and patients are relatively rare, so clinical misdiagnosis and missed diagnosis often occur; if not diagnosed and treated early, rapidly progressive lung and kidney damage directly threaten the patient's life safety. In recent years, the use of immunosuppressants has transformed AAV from a major life-threatening disease to a chronic disease that is prone to recurrence, and the toxic side effects of hormones and immunosuppressants, such as cardiovascular disease, infection, and thrombosis, directly endanger the patient's life and health and greatly reduce the quality of life.
[0003] Animal models are an extremely important experimental method and means in modern biomedical research. Humans can use animal models to study the occurrence, development and prevention and treatment of various diseases. Their advantages have won the favor of countless scientific researchers: 1. It avoids the risks of conducting experiments on humans; 2. Diseases that are not easily seen in clinical practice can be reproduced by animals at any time; 3. It can overcome the shortcomings of long incubation period, long course and low incidence of some human diseases; 4. It can strictly control experimental conditions and enhance the comparability of experimental materials; 5. It can simplify experimental operations and sample collection; 6. It helps to understand the nature of the disease more comprehensively. In view of the low incidence and substantial disease heterogeneity of AAV, people need to explore its intrinsic pathogenesis through animal models and find new directions for drug targeted therapy. So far, the common ways to construct animal models of ANCA-associated vasculitis (taking the animal model of MPO-AAV-associated experimental vasculitis as an example) are mainly: 1. Passive transfer of anti-MPO antibodies, splenocytes or MPO-specific T cells; 2. MPO active immune induction; 3. Drug induction method (combined administration of phorbol myristate acetate and propylthiouracil). The method for constructing the animal model of PR3-AAV is similar to the above method. The above modeling method has many shortcomings: 1. The pathological changes of most current animal models are milder than those of human diseases, and the relevance to human diseases needs to be further improved. 2. The modeling method is complicated and cumbersome, the experimental cycle is long, and most of them rely on the passive transfer of exogenous antibodies, which is not a true autoimmune reaction. 3. The antibodies / antigens used in the modeling method are expensive and difficult to obtain, which undoubtedly increases the experimental cost of modeling. Therefore, the above modeling method still needs to be improved. At present, the drug-induced AAV animal model is represented by the method of inducing MPO-AAV animal model with myristic acid phorbol acetate and propylthiouracil disclosed by Nakazawa et al.: the positive control group WKY rats were given oral PTU 10 mg / kg / day for 28 consecutive days, and 1ug PMA was injected intraperitoneally on days 0 and 7. WKY rats treated with these two drugs showed serum MPO-ANCA positivity, increased renal function indicators (serum urea nitrogen, creatinine), and proteinuria and hematuria tendency. Pathological results indicate that the lungs of rats induced by drugs show vasculitis-like changes, and the kidneys show focal segmental hyperplasia and inflammatory cell infiltration of glomeruli without immune complex deposition, which can damage the lungs and kidneys at the same time. The disadvantage is that the renal pathological changes are milder than those in humans, with only a small part of the glomeruli undergoing segmental hyperplasia with inflammatory infiltration, no crescent formation in the glomeruli, no cellulose exudation, etc. On the basis of the existing technology, the problem to be solved by the present invention is: aggravating the renal pathological changes of MPO-AAV rats, such as the kidneys showing crescentic glomerulonephritis / crescents in the glomeruli. Therefore, the present invention is boldly proposed. Summary of the invention
[0004] The purpose of the present invention is to provide an improved method for constructing an animal model of MPO-AAV-related experimental vasculitis, wherein PMA and PTU are used together to induce pathological changes such as pulmonary vasculitis, crescentic nephritis, and deterioration of renal function in animals in a state of depression, anxiety, endocrine abnormality, and susceptibility to stress. The safe drug dose can reduce the severity of pulmonary vasculitis in rats in a state of depression, anxiety, endocrine abnormality, and susceptibility to stress, and the duration of the pathological manifestations is also effectively prolonged.
[0005] In order to achieve the above objectives, the following technical solutions will be adopted:
[0006] A method for constructing an improved MPO-AAV-related experimental vasculitis animal model comprises the following steps: using phorbol myristate acetate (PMA) and propylthiouracil (PTU) to co-induce pathological changes such as pulmonary vasculitis, crescentic nephritis and deterioration of renal function in animals in a depressed, anxious, endocrine abnormal and easily stressed state.
[0007] Furthermore, the method for producing the depression, anxiety, endocrine abnormality and easy stress state is to select a specific strain of rats - Wistar Kyoto rats (WKY rats). WKY rats are obtained by inbreeding Wistar rats, have a specific genetic background, and need to be purchased in advance.
[0008] Furthermore, the WKY rats with depression, anxiety, endocrine abnormalities and prone to stress need to be fed with LAD001 feed or AIN93 standard feed. High-salt, high-sugar and high-fat feeds will affect the endocrine system and blood pressure of WKY rats.
[0009] Preferably, drinking water is provided 24 hours a day.
[0010] Furthermore, the WKY rats can be confirmed to be depressed, anxious, endocrine abnormal and prone to stress by strictly following the feeding method of LAD001 feed or AIN93 standard feed and providing the animals with a good living environment.
[0011] Furthermore, the method of co-inducing PMA and PTU comprises: intraperitoneally injecting PMA into WKY rats to induce NETs, and simultaneously administering oral PTU.
[0012] Furthermore, the WKY rats were intraperitoneally injected with PMA at a dose of 1 ug / day.
[0013] Furthermore, the WKY rats were intraperitoneally injected with PMA on day 0 and day 7 of modeling.
[0014] Furthermore, the WKY rats were orally administered PTU at a dosage of 20 mg / kg / day.
[0015] Furthermore, the WKY rats were administered with oral administration of PTU for 4 consecutive weeks.
[0016] Furthermore, the animal is a WKY rat, and the WKY rat is a male WKY rat.
[0017] Compared with the currently widely used modeling technology, the present invention has demonstrated several significant technical advantages in the field of constructing AAV (anti-neutrophil cytoplasmic antibody-associated vasculitis) rat models. These advantages not only deepen our understanding of the stability of disease models, but also greatly improve experimental efficiency and cost-effectiveness, opening up a new path for the study of AAV and related diseases.
[0018] (1) Innovative joint induction strategy
[0019] The present invention uses WKY (Wistar-Kyoto) rats as experimental subjects, and through a carefully designed PTU (propylthiouracil) daily oral dose doubling scheme, combined with PMA (phorbol-12-myristate-13-acetate), achieves efficient induction of AAV animal models. This strategy not only improves the stability and success rate of model construction compared to traditional methods, but also simplifies the operation process and reduces experimental costs. More importantly, it proves the feasibility of combined induction of PTU and PMA, provides more ideas and methods for the construction of animal models of AAV and even a wider range of autoimmune diseases, and greatly broadens the prospects of drug-induced animal models in scientific research and clinical applications.
[0020] (2) Models that closely mimic human disease characteristics
[0021] The present invention further explores the potential of double-dose PTU combined with PMA. This bold attempt not only makes the constructed AAV rat model reach new heights in stability, success rate and efficiency, but more importantly, the model is closer to the real situation of human MPO-AAV (myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis) in terms of pathological and physiological manifestations. Specifically, the positive expression of ANCA (anti-neutrophil cytoplasmic antibodies) in the serum of model rats, the clear presentation of pulmonary vasculitis-like lesions, and the significant increase in blood urea nitrogen and creatinine levels are all more accurate simulations of human disease characteristics. In addition, the hematuria and proteinuria associated with the active period, as well as the formation of focal segmental hyperplasia, inflammatory cell infiltration and crescentic glomerulonephritis in renal pathology, provide researchers with a more perfect disease simulation platform. This model not only provides a powerful tool for studying the pathogenesis of MPO-AAV, but also provides a reliable experimental model for exploring new therapeutic drugs and evaluating their efficacy, which has immeasurable practical value.
[0022] In summary, the research of this invention is not only an important innovation of the existing modeling technology, but also has important significance for promoting the research of AAV and related diseases to a deeper level. Its technical advantages and application potential will undoubtedly bring broader space and possibilities for future scientific research and clinical applications. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 This is a flow chart for constructing an animal model of MPO-AAV-related experimental vasculitis.
[0024] Figure 2 The following are the evaluation diagrams of renal function of MPO-AAV rats induced by propylthiouracil. Among them, (a) is the quantitative comparison of urine protein between the two groups of rats; (b) is the comparison of blood creatinine between the two groups of rats; (c) is the comparison of urea nitrogen between the two groups of rats.
[0025] Figure 3 This is a graph evaluating the MPO-ANCA level in MPO-AAV rats induced by propylthiouracil.
[0026] Figure 4 This is the immunofluorescence image of NETs in renal tissue of MPO-AAV rats induced by propylthiouracil.
[0027] Figure 5 This is a diagram of the pathological changes in lung tissue of MPO-AAV rats induced by propylthiouracil.
[0028] Figure 6 This is a diagram of the pathological changes in renal tissue of MPO-AAV rats induced by propylthiouracil. DETAILED DESCRIPTION
[0029] The present invention provides an improved method for constructing an MPO-AAV-related experimental vasculitis animal model, comprising: using PMA and PTU together to induce pathological changes such as pulmonary vasculitis lesions, crescentic nephritis, and renal function deterioration in animals in a state of depression, anxiety, endocrine abnormalities, and susceptibility to stress.
[0030] Phorbol myristate acetate (PMA), also known as TPA, is a phorbol ester PKC activator widely used in in vitro and in vivo experiments. MA binds to PKC (Ki = 2.6nM) and activates its function, showing an extremely broad inhibitory spectrum in both cells and tissues. PMA can inhibit Fas-induced apoptosis, but can induce apoptosis of HL-60 cells. PMA is a highly effective tumor promoter that can promote the formation of mouse skin tumors.
[0031] PMA, a classic inducer, can stimulate neutrophils to produce NETs. The process of PMA stimulating the formation of NETs in vivo is called NETosis. For example, after intraperitoneal injection of PMA into animals, it acts on protein kinase C (PKC), activates the Raf / MEK / ERK signaling pathway and nicotinamide adenine dinucleoside phosphate oxidase (NADPH, oxidase, NOX2), and induces the production of ROS. Then, core histone H3 / H4 undergoes citrullination under the action of peptidyl arginine deiminase 4 (PAD4), forming Cit-H3, which promotes the depolymerization of chromosomes in the nucleus of neutrophils. Subsequently, the nuclear morphology changes, the nuclear membrane ruptures to generate NETs, and NE and MPO are released. PMA applied to WKY rats can induce the production of NETs in vivo, thereby promoting NETosis. Excessive exposure of NETs damages the vascular endothelium and leads to inflammation. Therefore, the induction effect of PMA is of great significance in the construction of this model.
[0032] Propylthiouracil (PTU) is a thiourea antithyroid drug, a commonly used drug for the treatment of hyperthyroidism, which mainly inhibits the synthesis of thyroid hormones. Mechanism of action: By inhibiting thyroid peroxidase, it prevents the oxidation of iodide taken into the thyroid gland and the coupling of tyrosine, thereby inhibiting the synthesis of thyroxine (T4) and triiodothyronine. In addition, propylthiouracil also inhibits the deiodination of T4 in peripheral tissues to produce T3, causing the content of more active T3 in serum to decrease rapidly. It has been reported that PTU can induce anti-neutrophil cytoplasmic antibody-related small vessel vasculitis and can lead to autoimmune vasculitis. Patients who take PTU for a long time often have multiple organs involved in the body, especially the lungs and kidneys, accompanied by clinical symptoms such as fever, joint and muscle pain, rash, purpura, etc. Laboratory tests directly show elevated white blood cell index, positive C-reactive protein, elevated IgE, and positive ANCA.
[0033] The specific mechanism of PTU-induced AAV production is still unclear. Studies have shown that there may be a genetic background (closely related to HLA-DR3) in the production of PTU-induced ANCA-associated vasculitis. Some studies have also suggested that PTU can induce the production of ANCA, thereby triggering autoimmunity and leading to AAV. The animal model of MPO-AAV-associated experimental vasculitis induced by PTU drugs not only has the general commonalities of primary AA, but also has the characteristics of polyclonal autoimmune reactions of drug-induced vasculitis. It is expected to become an ideal model for studying the pathogenesis of ANCA-associated vasculitis and drug-targeted therapy.
[0034] The present invention combines depression, anxiety, endocrine abnormality and a stress state model based on the co-induction of PMA and PTU, which not only causes rats to develop pathological changes such as pulmonary vasculitis, crescentic nephritis and renal function deterioration that are often seen in clinical patients, but also aggravates the pathological changes and effectively prolongs the maintenance time of the pathological changes.
[0035] In some embodiments, the method for producing the depression, anxiety, endocrine abnormalities and easy stress state is to purchase a specific strain of rats - Wistar Kyoto rats (WKY rats).
[0036] WKY rats are derived from inbreeding of Wistar rats. They have a specific genetic background and are always in a state of depression, anxiety, endocrine abnormalities and susceptibility to stress.
[0037] In some embodiments, the method for maintaining a state of depression, anxiety, endocrine abnormalities and susceptibility to stress comprises: feeding with LAD001 feed or AIN93 standard feed.
[0038] In some embodiments, it is strictly forbidden to provide high-salt, high-sugar and high-fat feeds, which will affect the endocrine system and blood pressure of WKY rats.
[0039] In some embodiments, drinking water is provided 24 hours a day.
[0040] In some embodiments, strictly implementing the feeding method and providing the animals with a good living environment can confirm depression, anxiety, endocrine abnormalities, and susceptibility to stress.
[0041] In some embodiments, the method of co-inducing PMA and PTU comprises: intraperitoneal injection of PMA into an animal confirmed to be depressed, anxious, endocrine abnormal and prone to stress, and simultaneous oral administration of PTU.
[0042] In some embodiments, the dose of PMA injected intraperitoneally into WKY rats is 1 ug / day.
[0043] In some embodiments, the time of intraperitoneal injection of PMA into WKY rats is day 0 or day 7 of modeling.
[0044] In some embodiments, the oral PTU dose administered to WKY rats is 20 mg / kg / day.
[0045] In some embodiments, the administration cycle of PTU by oral gavage to WKY rats is from the first day of modeling and continued for 4 weeks.
[0046] When rats that have been confirmed to be depressed, anxious, have endocrine abnormalities, and are prone to stress are co-induced with PMA and PTU, the above-mentioned feeding methods must still be strictly followed and the animals must be provided with a good living environment.
[0047] In some embodiments, the animal is a WKY rat;
[0048] Preferably, the WKY rats are male WKY rats.
[0049] In some embodiments, the MPO-AAV-associated experimental vasculitis animal model constructed using the method of the present invention is often used to explore the pathogenesis of ANCA-associated vasculitis and targeted drug therapy.
[0050] The embodiments of the present invention will be described in detail below with reference to examples. The described embodiments are only used to illustrate and explain the present invention, and the present invention does not limit the scope of the invention. If no specific conditions are specified in the experimental examples, conventional methods can be used.
[0051] Example
[0052] like Figure 1As shown, the present invention constructs an MPO-AAV-related experimental vasculitis animal model by intraperitoneal injection of PMA (day 0 and day 7) combined with oral administration of PTU (for 4 consecutive weeks) in WKY rats. After the modeling, the pathological changes of the lung and kidney tissues of the rats were detected by HE staining, the expression and localization of NETs in the kidney tissues were observed by immunofluorescence staining, and the expression level of myeloperoxidase (MPO)-ANCA in the serum was detected by ELISA.
[0053] Experimental Materials
[0054] 1. Experimental Animals
[0055] Clean, healthy male SPF Wistar-Kyoto rats, 8-10 weeks old, weighing approximately 200-220 g, were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., animal license number SCXK (Beijing) 2021-0006. They were kept in the Experimental Animal Center of Guangxi Medical University, and all rats lived in a specific sterile environment with a room temperature of 22-26 ° C, a humidity of 40%-60%, and a light-dark cycle of 12h / 12h. All feed, drinking water and cages were sterilized by high pressure, the operating room was regularly ultraviolet disinfected, and rats were allowed to eat and drink freely for 24 hours. After one week of adaptive feeding, WKY rats were randomly divided into a control group and a model group. The rats in the control group were routinely fed and not given any special treatment. All procedures of this study, including research design, experimental protocols, and behaviors, were approved by the Ethics Committee of Guangxi Medical University.
[0056] 2. Main reagents
[0057] Phorbol myristic acid acetate (PMA) and propylthiouracil were purchased from Dalian Meilun Biotechnology Co., Ltd.; chloral hydrate was purchased from Shanghai Jizhi Biochemical Technology Co., Ltd.; 4% paraformaldehyde was purchased from Biosharp; urine visual detection test strips were purchased from Guilin Youlite Company; urine protein quantification kit, creatinine determination kit, and urea nitrogen determination kit were purchased from Nanjing Jiancheng Bioengineering Institute; rat MPO-ANCA IgG ELISA kit was purchased from Shanghai ELISA Biotechnology; rabbit anti-MPO antibody, hematoxylin stain, and eosin stain were purchased from Wuhan Sewell Biotechnology Co., Ltd.; neutral gum was purchased from Sinopharm Chemical Reagent Co., Ltd.
[0058] 3. Main instruments
[0059] Rotary microtome, ultrathin microtome - Leica Microsystems, Germany; Cryostat - Thermo Fisher Scientific, USA; Diamond microtome - Daitome; Automatic dehydrator - Wuhan Junjie Electronics Co., Ltd.; Tissue embedding machine - Changzhou Suburban Zhongwei Electronic Instrument Factory; Fully automatic staining machine - Changzhou Paisjie Medical Equipment Co., Ltd.; Pathological tissue bleaching and drying instrument - Changzhou Zhongwei Electronic Instrument Co., Ltd.; EVOS fluorescence microscope - Life Technologies, USA; Intelligent pathology microscope system - Olympus Corporation, Japan.
[0060] Experimental methods
[0061] 1. Construction of an animal model of MPO-AAV-related experimental vasculitis
[0062] Intraperitoneal injection of PMA: PMA was injected intraperitoneally into the WKY rats in the model group on the 0th and 7th days of modeling, respectively, at a dose of 1ug / day. PMA needed to be dissolved in PBS before intraperitoneal injection. Oral administration of PTU: The WKY rats in the model group were given oral administration of PTU at a dose of 20mg / kg / day. PTU was initially dissolved in alcohol and finally diluted with 5% glucose, with a final alcohol concentration of 1%. Oral administration cycle: Starting from the first day of modeling, the drug was administered continuously for 4 weeks. After 4 weeks, the animal model of MPO-AAV-related experimental vasculitis was completed.
[0063] 2. Collection and storage of rat urine specimens
[0064] At the end of the modeling cycle, use a high-pressure sterilized metabolic cage to collect 24-hour urine from each group of rats. Each rat is placed in a single cage, and they are fasting but not water. When assembling the metabolic cage, do not assemble it upside down to avoid contamination caused by rat feces mixed into the urine. The urine specimens collected at room temperature were allowed to stand for 2 hours, and then the urine specimens were centrifuged at 3600rpm for 15 minutes at 4°C. After centrifugation, the supernatant was taken and the obtained supernatant was divided into 1.5 ml EP tubes and frozen in a -80 degree Celsius refrigerator.
[0065] 3. Collection and storage of rat blood samples
[0066] After the urine collection is completed, blood samples are collected. Rats are anesthetized by intraperitoneal injection of 10% chloral hydrate at 0.3ml / 100g. After the injection of the anesthetic, the rats are fixed on the operating table in a supine position until the body becomes soft. The skin of the rat's abdomen is cut open in a "V" shape to expose the internal organs. Use a small piece of filter paper to gently push the intestine and fat to the left abdomen of the rat. Two large blood vessels can be seen in front of the spine. The slightly white one on the right is the abdominal aorta. In order to facilitate the observation of the amount of blood collected, the rat is turned 90° counterclockwise (90° clockwise when the left hand is inserted) and the head is placed in a supine position with the left side facing the head. The blood collection needle is installed, with the tip of the needle facing up, and the needle is inserted in front of the branch of the common iliac artery and moved forward slowly along the abdominal aorta. The needle tip is inserted deeper to prevent puncturing the blood vessel wall. Since the tail of the needle has been wrapped in a sealed latex tube, the blood will not flow out automatically. Slowly push the red-headed vacuum blood collection tube (without anticoagulant) for testing blood samples into the sleeve with the needle inside, so that the blood collection needle will penetrate into the blood collection tube, and blood will flow out. When the amount of blood reaches the required scale, the blood collection tube can be pulled out. At this time, the needle returns to the rubber tube, the blood is stopped, and other blood collection tubes are used for collection. In this way, multiple blood samples can be repeatedly collected for multiple index tests. After collecting enough blood samples, withdraw the needle from the blood collection tube. Let the collected blood sample stand for 2 hours at room temperature, and centrifuge the blood sample at 3000rpm at 4℃ for 10 minutes. The supernatant obtained from the homogenate obtained after centrifugation is retained, and the obtained supernatant is divided into 1.5 ml EP tubes and frozen in a -80 degree Celsius refrigerator.
[0067] 4. Kill the rats and take lung and kidney specimens
[0068] After the blood sample is collected, a longitudinal incision is made in the chest and abdomen of the rat to remove the lungs and kidneys of the rat, and the rat is killed by spinal method. The specimen can be divided into two parts, one part is used to make paraffin sections / frozen sections, and the other part is placed in a -80℃ refrigerator for freezing.
[0069] 5. Preparation of paraffin tissue sections
[0070] (1) Fixation: The removed lung and kidney tissue blocks are completely immersed in 4% paraformaldehyde for fixation. After the tissues are fixed, they are sealed and labeled with the source and date of the specimens. (2) Dehydration: In order to prevent the rat lung and kidney tissues from shrinking strongly, the fixed lung and kidney tissues should be placed in a gradient of ethanol from low to high concentrations (50%, 70%, 80%, 95%, 100%) for 45 minutes at each level to completely remove the moisture from the tissues. Dehydration must be performed in a sealed container because high concentration ethanol easily absorbs moisture from the air. Adding an equal amount of glycerol can preserve the specimens for a long time. (3) Transparency: The completely dehydrated lung and kidney tissue blocks are completely immersed in an equal volume mixture of pure ethanol and xylene, and then immersed in pure xylene for transparency for 1.5 hours. The pure xylene should be replaced twice, and the total time should not exceed 3 hours. When using xylene for transparency, it must also be done in a covered container to avoid absorbing moisture and volatilization in the air, so as to maintain its anhydrous state. (4) Wax dipping: The wax dipping process must be completed in a thermostatic box, and the temperature in the box should be maintained at about 50-60°C. The transparent lung and kidney tissue blocks are treated with a mixture of paraffin and xylene (1:1 ratio) and pure paraffin in turn. Pure paraffin treatment is performed 3 times, each time for 30 minutes. The wax dipping time should not be too long, and the temperature should not be too high, so as to avoid the tissue becoming brittle. (5) Embedding: Pour the molten wax into the prepared embedding frame, quickly pick up the wax-dipping tissue block with pre-warmed tweezers, put it into the pure wax with the cut surface facing down, and immediately put it into cold water to accelerate cooling and solidification, and then take it out after 30 minutes. The wax penetration temperature should be slightly lower than the temperature of the embedding wax to ensure that the tissue block and the molten wax are completely integrated. (6) Sectioning: Adjust the angle between the tissue section and the blade plane to about 15°, and install the wax block on the slicer, with the upper and lower edges of the wax block parallel to the blade. Adjust the thickness regulator to the required section thickness. The thickness of lung tissue and kidney tissue is about 4μm and 2μm, respectively. In the process of making tissue sections, a moderate slicing speed and the force of the shaking wheel can avoid uneven slice thickness. (7) Pasting: Put the sliced sections into a warm water bath. The sections will naturally stretch out due to the surface tension of the water. Insert the glass slide coated with 5% gelatin aqueous solution obliquely into the water surface to pick up the required sections. Make sure the sections are flatly attached to the appropriate position of the glass slide and place them in a 45°C constant temperature oven to dry. It is worth noting that the glass slide used must be kept clean and free of oil stains. The shiny side of the sections should face down to avoid discoloration.
[0071] 6. HE staining of lungs and kidneys
[0072] (1) Dewaxing: Place the prepared paraffin sections of lung tissue and kidney tissue in xylene I and II for 10 minutes each, and then place the sections in ethanol from high to low concentrations for hydration to make it easier for the dye to enter the tissue. (2) Staining: Stain the sections with hematoxylin solution for 5 minutes. The staining time can be appropriately increased or decreased according to the actual staining situation. After taking out, rinse with running water. (3) Differentiation and rinsing: Place the tissue sections in 1% hydrochloric acid ethanol differentiation solution for 30 seconds, rinse with running water for 1 minute, treat with 1% ammonia blue solution for 30 seconds, and rinse with running water for 1 minute. (4) Restaining: Stain the tissue sections with 0.5% alcohol-soluble eosin staining solution for 30 seconds. (5) Dehydration: Dehydrate the tissue sections in ethanol from low to high concentrations in a gradient manner, and absorb the excess ethanol with absorbent paper. (6) Transparenting: Place the dehydrated paraffin sections in xylene for three times, each time for 3 minutes. (7) Sealing: The tissue sections treated as above are sealed and stored between a glass slide and a cover slip. The concentration of the gum used should be moderate.
[0073] 7. Detection of MPO in rat kidney tissue
[0074] (1) Dehydration: Place rat kidney tissue in a 20% to 30% sucrose solution for 1 to 3 days. Use hypertonicity to absorb tissue moisture and reduce tissue water content. (2) Embedding: Remove the tissue, wash with pre-cooled PBS, and place it flat in a soft plastic bottle cap or a special small box. Add an appropriate amount of OCT embedding agent to immerse the tissue for embedding. Then slowly place the special small box flat in a small cup filled with liquid nitrogen. When the bottom of the box contacts the liquid nitrogen, it begins to vaporize and boil. At this time, the small box remains in place and should not be immersed in liquid nitrogen. The tissue will quickly freeze into blocks in about 10 to 20 seconds. (3) Sectioning and fixation: Remove the tissue ice and immediately place it in a constant temperature box slicer for frozen sectioning with a thickness of 4 μm. Place the cut frozen sections in a 37°C oven for 10 to 20 minutes to dry the moisture. Then fix them in the fixative for 30 minutes, place them in PBS (PH7.4) and shake them on a decolorizing shaker to wash them 3 times, 5 minutes each time. (4) Antigen retrieval: Use citric acid for antigen retrieval. During the repair process, be careful to prevent excessive evaporation of the buffer and avoid dry sections. After repair, cool naturally. Then place the slide in PBS (PH7.4) and shake on a decolorizing shaker to wash 3 times, 5 minutes each time. The above is the process of making frozen sections. (5) Circle serum blocking: After the slices are slightly dried, use an immunohistochemistry pen to draw circles around the tissue, add BSA (if the primary antibody is from goat, use 10% donkey serum to block, and if the primary antibody is from other sources, use 3% BSA to block), and block for 30 minutes. (6) Incubation antibody: Add the prepared anti-MPO antibody (1:200), and place the slices flat in a humidified box and incubate overnight at 4°C. After the primary antibody incubation is completed, wash the slides again with PBS and shake on a shaker 3 times, 5 minutes each time. Add CY3-labeled goat anti-rabbit IgG (1:300) and incubate at room temperature away from light for 50 minutes. (7) Counterstaining of cell nuclei: After the secondary antibody incubation is completed, wash the slides 3 times with PBS, 5 minutes each time. Add DAPI staining solution and incubate at room temperature away from light for 10 minutes. (8) Quenching tissue autofluorescence: Place the slide in PBS (PH7.4) and wash on a decolorizing shaker for 3 times, 5 minutes each time. Add autofluorescence quencher B solution for 5 minutes and rinse with running water for 10 minutes. (9) Sealing: Sealing with anti-fluorescence quenching sealing agent. (10) Image acquisition: Observe under an EVOS fluorescence microscope, DAPI excitation wavelength 330 ~ 380nm, emission wavelength 420nm, cell nucleus is blue: CY3 excitation wavelength 510 ~ 560nm, emission wavelength 590nm, MPO positive site is red.
[0075] 8. Detection of ANCA titer in rat serum
[0076] The ELISA kit was used to detect the level of myeloperoxidase-specific anti-neutrophil IgG antibody (MPO-ANCA IgG) in rat serum.
[0077] Preparations before testing: (1) Take the test kit out of the 4°C refrigerator half an hour in advance and wait for the temperature to equilibrate to room temperature (20-25°C). If the concentrated washing solution taken out of the refrigerator has crystals attached to it, this is a normal phenomenon. Place it at room temperature and wait for the crystals to fully dissolve before preparing the washing solution. (2) Prepare the working washing solution: Prepare the distilled water required for the test in advance to dilute the concentrated washing solution. Dilute 20× washing buffer and distilled water at a ratio of 1:20, that is, add 20mL 20× washing buffer to 400mL of distilled water to prepare the working concentration of washing solution. The unused amount can be stored at 4°C. (3) Calibrate the micropipette (10ul, 100ul, 200μl, 1000μl, etc.) to minimize experimental errors. Sample processing and requirements: The sample for this test is rat serum. The collected whole blood is centrifuged and the upper serum is taken. After aliquoting, it is frozen in a -20°C or -80°C refrigerator to avoid repeated freezing and thawing. Operation steps: (1) Calculate the number of standards and samples to be tested, set up 2 to 3 replicate wells, take out the strips in the aluminum foil bag from the refrigerator, equilibrate to room temperature and start using, take out the required strips according to the total number of samples, put the excess strips and desiccant back into the tin foil bag and store in a 4°C refrigerator. (2) Sample addition: Set up standard wells and sample wells, add 50 μL of standards of different concentrations to the standard wells, add 50 μL of the sample to be tested to the sample wells; do not add to the blank wells. If the sample needs to be diluted, dilute the sample with the sample diluent provided in the actual box as required. (3) Add 50 μL of biotin-labeled antibody to each well, cut a sealing film of appropriate size, seal the reaction wells, and place in a 37°C constant temperature box for incubation for 30 minutes; do not add to the standard wells or blank wells. (4) Discard the liquid in the wells, pat dry on absorbent paper, fill each well with washing solution (350 μL), let stand for 1 min, shake off the washing solution, pat dry on absorbent paper, and repeat the washing process 5 times (you can also use a plate washer to wash the plate). (5) Except for the blank wells, add 100 μL of horseradish peroxidase (HRP)-labeled detection antibody to each well of the standard well and sample well, seal the reaction wells with a sealing film, and incubate in a 37°C water bath or incubator for 30 min. (6) Perform the same operation as step (4) and repeat 5 times. (7) Add 50 μL of substrate A and B to each well and incubate at 37°C in the dark for 15 min. (8) Add 50 μL of stop solution to each well and measure the OD value of each well at a wavelength of 450 nm on an ELISA reader within 15 min and record it. (9) Draw a standard curve and calculate the experimental results. In the Excel worksheet, use the standard concentration as the horizontal axis (the standard concentrations are: 100, 50, 12.5, 6.25, 0 ng / mL), and the corresponding OD value as the vertical axis to draw the standard linear regression curve, and calculate the concentration value of each sample according to the curve equation.
[0078] 9. Urine protein test
[0079] The urine protein concentration of rats was detected using a urine protein quantification kit, CCB method: (1) Preparation of CCB application solution: Prepare CCB reagent: double distilled water in a ratio of 1:4, i.e., 5-fold dilution. (2) Sample addition: Prepare blank tubes, standard tubes, and assay tubes and mark them. First, add 3.0 mL of CCB application solution to each tube. Next, add 0.05 mL of double distilled water to the blank tube, 0.05 mL of protein standard solution to the standard tube, and 0.05 mL of the sample to be tested to the assay tube. Mix thoroughly and let stand at room temperature for 5 min. Take 0.2 mL from each tube to a 96-well plate (be careful not to add bubbles), turn on the microplate reader, read and record at 595 nm. (3) The urine protein concentration is calculated using formula 1 (the standard concentration is 524 mg / L).
[0080] Formula 1:
[0081]
[0082] 10. Creatinine test
[0083] Use the creatinine (Cr) assay kit to detect the serum creatinine content of rats, sarcosine oxidase method: (1) Prepare a 96-well plate, mark the blank well, standard well and assay well, first, add 180 μL of enzyme solution A to each well, then add 6 μL of double distilled water to the blank well, 6 μL of standard to the standard well, and 6 μL of the sample to be tested to the assay well. Mix thoroughly to avoid bubbles, incubate at 37°C for 5 minutes, and measure the absorbance value A1 at a wavelength of 546 nm. (2) Add 60 μL of reagent II enzyme solution B to each well, incubate at 37°C for 5 minutes, and measure the absorbance value A2 at a wavelength of 546 nm. (3) Calculate ΔA=A2-K×A1, K is calculated according to formula 2, and the serum creatinine content is calculated according to formula 3 (the concentration of the standard is 442 μmol / L).
[0084] Formula 2:
[0085]
[0086] Formula 3:
[0087]
[0088] 11. Urea nitrogen detection
[0089] Use the urea nitrogen (BUN) test kit to detect the urea nitrogen concentration of rats, urease method: (1) Preparation of buffered enzyme solution: Prepare the buffered enzyme solution according to the ratio of enzyme stock solution: enzyme diluent = 3:1000 before use, and prepare it before use. (2) Preparation of BUN stock solution: Take 1 powder and add 1mL double distilled water to prepare 100mmol / L standard stock solution before use, and store it at 4℃. (3) Preparation of BUN standard application solution: Dilute the 100mmol / L standard stock solution with double distilled water at a ratio of 1:9 (i.e. 10 times dilution) to prepare 10mmol / L BUN standard application solution, and store it at 4℃ for 2 to 3 days. (4) Sample addition: Prepare blank tubes, standard tubes and test tubes and mark them. First, add 0.25 mL of buffered enzyme solution to each tube. Then, add 0.02 mL of double distilled water to the blank tube, 0.02 mL of 10 mmol / L BUN standard application solution to the standard tube, and 0.02 mL of the sample to be tested to the test tube. Mix well and incubate at 37°C for 10 min. (5) Add 1 mL of reagent diphenol colorimetric agent and reagent tribasic sodium hypochlorite to each tube, mix well and incubate at 37°C for 10 min. (6) Take 0.2 mL from each tube to a 96-well plate (be careful not to add bubbles), turn on the microplate reader, read and record at 640 nm. (7) Calculate urine protein concentration using formula 4.
[0090] Formula 4:
[0091]
[0092] Statistical methods
[0093] The quantitative data that conform to the normal distribution are expressed as x±s and the median M(P 25 ,P 75 ) was used to describe data that did not conform to normal distribution. Two independent sample t-tests were used to compare the two groups. All data were analyzed using SPSS26.0 software, and graphs were drawn using GraphPad Prism 8.0 software. P<0.05 was considered statistically significant.
[0094] Experimental Results
[0095] Identification of MPO-AAV Animal Model
[0096] Figure 2It showed a significant difference in serum renal function levels between the normal control group and the model group. Specifically, compared with the Control group, the urine protein quantification of rats in the MPO-AAV group showed a significant upward trend. This change directly reflects the impairment of renal filtration function and may be related to the increased permeability of the glomerular basement membrane. At the same time, the increase in blood urea nitrogen levels is also a clear sign of impaired renal function, which reveals the accumulation of protein metabolites in the body, and further confirms that the renal function of rats in the MPO-AAV group is significantly affected (all P<0.05). It is worth noting that although the statistical analysis of blood creatinine levels between the two groups showed that the difference did not reach statistical significance (P>0.05), the blood creatinine levels of rats in the MPO-AAV group still showed an upward trend, which may indicate an early sign of renal damage and provide an important early warning signal for subsequent studies.
[0097] Figure 3 Focusing on the comparison of MPO-ANCA (myeloperoxidase anti-neutrophil cytoplasmic antibodies) levels, the results clearly showed that in the MPO-AAV group of rats, the MPO-ANCA level was significantly increased compared with the Control group (P<0.05). This result not only strengthens the effectiveness of the drug-induced MPO-AAV rat model, but also reveals the key role of MPO-ANCA in the progression of MPO-ANCA. As an autoantibody, MPO-ANCA binds to target antigens on the surface of neutrophils, induces excessive activation of neutrophils, leads to abnormal production of cytokines, and is accompanied by the release of reactive oxygen species and lytic enzymes, thereby damaging vascular endothelial cells and promoting the development of MPO-AAV.
[0098] Figure 4 The expression of NETs (neutrophil extracellular traps) in the renal tissues of the two groups of rats was shown. The results showed that the expression of MPO in the renal tissues of rats in the MPO-AAV group was significantly enhanced, and this change was closely related to the formation of NETs. As a key component of NETs, the high expression of MPO means that neutrophils and NETs appear and infiltrate in renal tissues. NETs contain proinflammatory proteins, which may directly promote vascular inflammation by destroying endothelial cells and activating the complement system, and indirectly promote vascular inflammation by producing MPO-ANCA as a link between the innate immune system and the adaptive immune system, thereby accelerating kidney damage in MPO-AAV rats.
[0099] Figure 5 and Figure 6 The changes in lung and kidney tissue pathology between the normal control group and the model group are shown respectively. Figure 5In the study, the lung tissue of rats in the Control group showed normal tissue structure without obvious pathological changes. However, the lung tissue of rats in the MPO-AAV group suffered significant damage, as shown by the infiltration of a large number of inflammatory cells and alveolar hemorrhage. This pathological change suggests that the lung, as one of the common target organs affected by MPO-AAV, has been damaged, reflecting the effectiveness of the drug-induced MPO-AAV rat model. Figure 6 In the experiment, the renal tissue of rats in the Control group also remained intact and no abnormalities were found. However, the renal tissue of rats in the MPO-AAV group showed crescents, a typical MPO-AAV renal pathological change, which means that the pathological changes in the MPO-AAV rat model are more consistent with the manifestation of human diseases. The kidney is the most commonly affected organ by MPO-AAV. The formation of crescents means severe damage to the glomerular filtration function and irreversible damage to the kidney structure, which indicates rapid disease progression and poor prognosis.
[0100] In summary, these experimental results not only confirm the effectiveness of the MPO-AAV model in inducing the occurrence and development of myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis, but also reveal the important role of multiple biomarkers and pathological changes in disease progression, providing valuable experimental basis for a deeper understanding of the pathogenesis and treatment strategies of ANCA-associated vasculitis.
[0101] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A method for constructing an improved MPO-AAV-related experimental vasculitis animal model, characterized in that: The method comprises the following steps: using phorbol myristate acetate and propylthiouracil to induce pathological changes of pulmonary vasculitis, crescentic nephritis and deterioration of renal function in animals in a state of depression, anxiety, endocrine abnormality and easy stress.
2. The improved method for constructing an animal model of MPO-AAV-related experimental vasculitis according to claim 1, characterized in that: The method for producing the depression, anxiety, endocrine abnormality and easy stress state is to select a specific strain of rats, namely WKY rats, which are obtained by inbreeding Wistar rats.
3. The improved method for constructing an animal model of MPO-AAV-related experimental vasculitis according to claim 2, characterized in that: The WKY rats were fed with LAD001 feed or AIN93 standard feed.
4. The improved method for constructing an animal model of MPO-AAV-related experimental vasculitis according to claim 3, characterized in that: The WKY rats can be confirmed to be depressed, anxious, endocrine abnormal and easily stressed by strictly following the feeding method of LAD001 feed or AIN93 standard feed and providing the animals with a good living environment.
5. The improved method for constructing an animal model of MPO-AAV-related experimental vasculitis according to claim 1, characterized in that: The method for co-inducing phorbol myristate acetate and propylthiouracil comprises: intraperitoneally injecting PMA into WKY rats to induce NETs, and simultaneously administering oral PTU.
6. The improved method for constructing an animal model of MPO-AAV-related experimental vasculitis according to claim 5, characterized in that: The WKY rats were intraperitoneally injected with PMA at a dose of 1 ug / day.
7. The improved method for constructing an animal model of MPO-AAV-related experimental vasculitis according to claim 5, characterized in that: The WKY rats were intraperitoneally injected with PMA on day 0 and day 7 of modeling.
8. The improved method for constructing an animal model of MPO-AAV-related experimental vasculitis according to claim 5, characterized in that: The WKY rats were orally administered PTU at a dose of 20 mg / kg / day.
9. The improved method for constructing an animal model of MPO-AAV-related experimental vasculitis according to claim 5, characterized in that: The WKY rats were administered oral PTU for 4 consecutive weeks.
10. The improved method for constructing an animal model of MPO-AAV-related experimental vasculitis according to claim 1, characterized in that: The animals are WKY rats, and the WKY rats are male WKY rats.
